Harvard Bioscience (HBIO) Income from Continuing Operations (2010 - 2026)
Harvard Bioscience (HBIO) reported Income from Continuing Operations of 3424000.0 for Q1 2026, up 93.19% year-over-year from 1772329.83 in Q1 2025, and down 0.71% quarter-over-quarter from 3400000.0 in Q4 2025.
Harvard Bioscience (HBIO) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Harvard Bioscience (HBIO) has 17 years of Income from Continuing Operations data on file, last reported at 3424000.0 in Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 3424000.0, up 93.19% year-over-year; the trailing twelve-month figure through Mar 2026 was 10337000.0 (up 82.16% YoY), and the FY2025 annual result was 57253000.0, down 361.53% from the prior year.
- Income from Continuing Operations declined to 3424000.0 in Q1 2026 per HBIO's latest filing, from 3400000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 2421000.0 in Q2 2022 and troughed at 50294000.0 in Q1 2025.
- A 5-year average of 5072176.47 and a median of 2282000.0 in 2025 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2022 and 2025: Income from Continuing Operations jumped 660.42% in 2022, then slumped 18988.89% in 2025.
- A 5-year view of Income from Continuing Operations shows it stood at 2164000.0 in 2022, then gained by 26.52% to 1590000.0 in 2023, then soared by 101.13% to 18000.0 in 2024, then tumbled by 18988.89% to 3400000.0 in 2025, then retreated by 0.71% to 3424000.0 in 2026.
- Business Quant data shows HBIO's Income from Continuing Operations at 3424000.0 in Q1 2026, 3400000.0 in Q4 2025, and 1231000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | 826.00 Mn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -37.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | 239.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | 398.73 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | 135.40 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | 13.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -77.90 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | 112.77 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -17.00 Mn |
| 10 | Harvard Bioscience | 26.17 Mn | 19.07 Mn | 12.24 Mn | -3.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.42 Mn |
| Dec 31, 2025 | -3.40 Mn |
| Sep 30, 2025 | -1.23 Mn |
| Jun 30, 2025 | -2.28 Mn |
| Mar 31, 2025 | -50.29 Mn |
| Dec 31, 2024 | 18,000.00 |
| Sep 30, 2024 | -4.80 Mn |
| Jun 30, 2024 | -2.88 Mn |
| Mar 31, 2024 | -4.69 Mn |
| Dec 31, 2023 | -1.59 Mn |
| Sep 30, 2023 | -1.24 Mn |
| Jun 30, 2023 | -980,000.00 |
| Mar 31, 2023 | 622,000.00 |
| Dec 31, 2022 | -2.16 Mn |
| Sep 30, 2022 | -3.39 Mn |
| Jun 30, 2022 | 2.42 Mn |
| Mar 31, 2022 | -6.92 Mn |
| Dec 31, 2021 | 590,000.00 |
| Sep 30, 2021 | -170,000.00 |
| Jun 30, 2021 | -432,000.00 |